Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Effects on Cardiac Structure in Type 2 Diabetes (EMPA-HEART)
NCT02998970Phase 4Unknown
- Sponsor
- Unity Health Toronto
- Start
- Jan 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Change in Left Ventricular Mass at 6 months. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT02998970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998970.